Jonathon Carll1,2,3,*, Jacinta Bonaddio1, Dixon Woon1,4,5, Marlon Perera1,4,5,6, Nathan Lawrentschuk2,3,5,6, Thilakavathi Chengodu1,3
Canadian Journal of Urology, Vol.33, No.1, pp. 21-34, 2026, DOI:10.32604/cju.2025.068908
- 28 February 2026
Abstract Prostate-specific membrane antigen (PSMA) is a surface membrane antigen that is highly overexpressed in prostate cancer, with heterogenous expression throughout the natural history of the disease. This has generated significant interest as a potential biomarker for use in early diagnosis and treatment of prostate cancer. We reviewed the literature surrounding PSMA and its current clinical applications in diagnosing and managing early prostate cancer that is confined to the prostate and local lymph nodes. A search on PubMed, Medline, and Web of Science was performed using the following keywords: “PSMA”, “Prostate Specific Membrane Antigen”, “Prostate cancer”,… More >